HK Stock Market Move | LAEKNA-B (02105) surged by up to 36% in the afternoon, reaching a cooperation agreement with Eli Lilly in the United States on the treatment of obesity with LAE102.

LAEKNA-B (02105) rose by a maximum of 36% in the afternoon, reaching an increase of 26.04% at the time of the report, at a price of 13.36 Hong Kong dollars, with a turnover of 3.04 billion Hong Kong dollars. On the news front, Laike Pharmaceutical announced at noon that the group has signed a clinical cooperation agreement with Lilly to support and accelerate the global clinical development of LAE102 for the treatment of obesity. Lilly will be responsible for conducting a Phase I study in the United States and covering related costs. The group will retain global rights to LAE102. It is reported that LAE102 is a monoclonal antibody developed independently targeting Act RIIA, a receptor that plays an important role in muscle regeneration and fat metabolism. In preclinical models, LAE102 has shown effects of increasing muscle and reducing fat. When used in combination with GLP-1 receptor agonists, LAE102 can further reduce fat and significantly decrease muscle loss caused by GLP-1 receptor agonists, making LAE102 a high-quality candidate for weight control.